International Stem Cell's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 29.84.
International Stem Cell's Days Inventory for the
three
months ended in Mar. 2026 was 157.2.
International Stem Cell's Days Payable for the
three
months ended in Mar. 2026 was 28.93.
Therefore, International Stem Cell's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 158.11.
International Stem Cell (OTCPK:ISCO) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
International Stem Cell Cash Conversion Cycle Related Terms
International Stem Cell Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for International Stem Cell's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
International Stem Cell Cash Conversion Cycle Chart
ISCO vs ZVSA, AXIM, HEPA: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, International Stem Cell's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
International Stem Cell Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, International Stem Cell's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where International Stem Cell's Cash Conversion Cycle falls into.
International Stem Cell Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
International Stem Cell's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
International Stem Cell (ISCO) has a Cash Conversion Cycle of 158.11 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on International Stem Cell and its competitors.
Is International Stem Cell's Cash Conversion Cycle too high?
International Stem Cell's current Cash Conversion Cycle is 158.11. The Biotechnology industry median Cash Conversion Cycle is 104.03. International Stem Cell's value of 158.11 is 52% above this industry median. Overall, International Stem Cell has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does International Stem Cell's Cash Conversion Cycle compare to ZVSA and AXIM?
International Stem Cell's Cash Conversion Cycle of 158.11 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 104.03. International Stem Cell's value of 158.11 is 52% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 104.03, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. International Stem Cell's current Cash Conversion Cycle of 158.11 is 52% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on International Stem Cell and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. International Stem Cell's current Cash Conversion Cycle is 158.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is International Stem Cell stock overvalued right now?
Based on GuruFocus' analysis, International Stem Cell (ISCO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.18 — trading 37.7% above its estimated fair value. The current Cash Conversion Cycle is 158.11 and 52% above the Biotechnology industry median of 104.03. International Stem Cell's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For International Stem Cell (ISCO), the current Cash Conversion Cycle is 158.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is International Stem Cell (ISCO) Overvalued in 2026?
Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued.
The current stock price of $0.18 is trading 37.7% above its estimated GF Value™ of $0.13.
GuruFocus considers International Stem Cell to be Significantly Overvalued.
Key valuation signals for ISCO:
Cash Conversion Cycle: 158.11
GF Value™: $0.13 vs. price of $0.18 (37.7% above fair value)
Industry Position: 52% above the Biotechnology median
No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
24GF Score
Get the complete analysis for ISCO
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISCO has been successfully added to your 
